CV Sciences (OTCMKTS:CVSI – Get Free Report) and Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.
Earnings & Valuation
This table compares CV Sciences and Collegium Pharmaceutical”s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
CV Sciences | $15.70 million | 0.43 | -$2.39 million | N/A | N/A |
Collegium Pharmaceutical | $631.45 million | 1.63 | $69.19 million | $1.22 | 26.23 |
Volatility and Risk
CV Sciences has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and target prices for CV Sciences and Collegium Pharmaceutical, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
CV Sciences | 0 | 0 | 0 | 0 | 0.00 |
Collegium Pharmaceutical | 0 | 1 | 3 | 0 | 2.75 |
Collegium Pharmaceutical has a consensus price target of $43.75, indicating a potential upside of 36.72%. Given Collegium Pharmaceutical’s stronger consensus rating and higher possible upside, analysts clearly believe Collegium Pharmaceutical is more favorable than CV Sciences.
Profitability
This table compares CV Sciences and Collegium Pharmaceutical’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
CV Sciences | -12.25% | -89.43% | -22.75% |
Collegium Pharmaceutical | 6.61% | 99.08% | 15.14% |
Summary
Collegium Pharmaceutical beats CV Sciences on 10 of the 10 factors compared between the two stocks.
About CV Sciences
CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.